To compare the effects of AKT-1 and pan-AKT inhibition on human NSCLC cell proliferation, six NSCLC cell lines were treated with increasing doses of both A-674563 and MK-2206 over a 72-hour period. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.